{"pub": "dailymail", "url": "https://dailymail.co.uk/money/markets/article-7597533/GlaxoSmithKline-selling-two-anti-rabies-vaccines-Danish-rival-822m.html", "downloaded_at": "2019-10-22 13:39:03.840839+00:00", "title": "GlaxoSmithKline selling two anti-rabies vaccines to a Danish rival for \u00a3822m", "language": "en", "text": "GlaxoSmithKline is selling two anti-rabies vaccines to a Danish rival for \u00a3822m.\n\nThe British drugs group said the sale of anti-rabies treatment Rabipur and Encepur to Bavarian Nordic includes an upfront payment of \u00a3259m and later payments of up to \u00a3563m.\n\nGSK's boss Emma Walmsley is continuing with an overhaul of the company, which is posed for a fresh push into the lucrative cancer drug market.\n\nSign of the times: GSK's boss Emma Walmsley is continuing with an overhaul of the company\n\nSince taking over in 2017, Walmsley has sought to focus on GSK's pharmaceuticals business with a plan that will culminate in the demerger of the consumer division in 2021.\n\nRoger Connor, president of global vaccines at GSK, said: 'This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our research and development pipeline.'\n\nGSK acquired the two vaccines from Novartis in 2015 as part of an asset swap in which it sold its cancer drugs business to its Swiss rival.\n\nGSK reported revenue of \u00a35.9 billion from its vaccines segment in 2018.\n\nThe company said both vaccines will continue to be manufactured at its Marburg site in Germany until full production is transferred to Bavarian Nordic within five years.\n\nShares in Glaxosmithkline fell after the announcement yesterday, however, closing 0.4 per centlower, or 6.4p, at 1639.8p.", "description": "The British drugs group said the sale of anti-rabies treatment Rabipur and Encepur to Bavarian Nordic includes an upfront payment of \u00a3259m and later payments of up to \u00a3563m.", "authors": ["City", "Finance Reporter For The Daily Mail", "Some Links In This Article May Be Affiliate Links. If You Click On Them We May Earn A Small Commission. That Helps Us Fund This Is Money", "Keep It Free To Use. We Do Not Write Articles To Promote Products. We Do Not Allow Any Commercial Relationship To Affect Our Editorial Independence."], "top_image": "https://i.dailymail.co.uk/1s/2019/10/21/20/20004218-0-image-a-13_1571685354700.jpg", "published_at": "2019-10-21"}